Santen Enters into a Strategic Cooperation with OFF Italia to Offer New Treatment Options to its Customers Across EMEA

OFF Italia and Santen entered into a licence and supply agreement with the objective to extend the offering of OFF Italia’s ophthalmic innovations to more than 30 countries across EMEA.

According to the terms of the agreement, OFF Italia, an Italian company established in 2014 by senior executives within ophthalmology, has granted to Santen the rights to commercialize five products from its eye care portfolio.

The rights include the possibility to co-develop new products or build upon existing product lines to respond flexibly to patient and physician needs. The focus of this collaboration will be to identify new therapeutic solutions and innovative formulations with solid therapeutic efficacy and tolerability. This will enable the improvement of outcomes within retinal pathologies, ocular surface disorders, eye care, glaucoma, and ophthalmic surgery

“We are very pleased to enter into this strategic collaboration with OFF Italia as we wish to complement our prescription medicines with selected over-the-counter treatment options, especially within Santen’s dry eye disease portfolio,” Luís Iglesias, President and Head of Santen EMEA, said in a company news release. “OFF Italia’s scientific and customer-orientated approach in the development of improved or new treatment options is compelling. These are values that Santen shares to a great extent with OFF Italia, aiming to serve our customers’ needs.”

“OFF Italia was searching for a partner to commercialize its own innovative therapeutic solutions in Europe and beyond, entering in a strategic R&D collaboration with a major player in the ophthalmic area. We are delighted to announce the partnership with Santen,” said Alessando Zanini, CEO, OFF Italia.